Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.
Sign Up to like & getrecommendations! Published in 2023 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2023.0655
Abstract: Importance Current third-line therapies for patients with metastatic colorectal cancer (MCRC) have limited efficacy. Rechallenge with epidermal growth factor receptor (EGFR) inhibitors for RAS wild-type (WT) MCRC may be valuable for these patients. Objective To… read more here.
Keywords: refractory ras; therapy; panitumumab plus; plus trifluridine ... See more keywords
Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-017-1220-0
Abstract: BackgroundThe RECOURSE trial showed clinical efficacy for trifluridine/tipiracil for refractory metastatic colorectal cancer patients. We assessed the feasibility and effectiveness of trifluridine/tipiracil in daily clinical practice in The Netherlands.MethodsMedical records of patients from 17 centers… read more here.
Keywords: metastatic colorectal; trifluridine tipiracil; tipiracil; feasibility effectiveness ... See more keywords
An exploration of trifluridine/tipiracil in combination with irinotecan in patients with pretreated advanced gastric cancer
Sign Up to like & getrecommendations! Published in 2022 at "Investigational New Drugs"
DOI: 10.1007/s10637-022-01223-9
Abstract: Background. Trifluridine/tipiracil (FTD/TPI) and irinotecan are treatment options for heavily pretreated patients with advanced gastric cancer, but their efficacies are limited. We investigated the combination of FTD/TPI and irinotecan for such patients. Methods. Patients who… read more here.
Keywords: level; trifluridine tipiracil; advanced gastric; gastric cancer ... See more keywords
Post-marketing surveillance study of trifluridine/tipiracil in patients with metastatic colorectal cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Japanese journal of clinical oncology"
DOI: 10.1093/jjco/hyaa243
Abstract: BACKGROUND The novel oral nucleoside antineoplastic agent trifluridine/tipiracil was approved for metastatic colorectal cancer in Japan in March 2014. In this post-marketing surveillance study, we investigated the safety and efficacy of trifluridine/tipiracil in a real-world… read more here.
Keywords: metastatic colorectal; trifluridine tipiracil; tipiracil; colorectal cancer ... See more keywords
Integrated safety summary for trifluridine/tipiracil (TAS-102)
Sign Up to like & getrecommendations! Published in 2018 at "Anti-Cancer Drugs"
DOI: 10.1097/cad.0000000000000554
Abstract: Trifluridine/tipiracil, an oral treatment combining trifluridine (an antineoplastic thymidine-based nucleoside analog) and tipiracil hydrochloride (a thymidine phosphorylase inhibitor), led to significant improvement in overall survival in metastatic colorectal cancer (mCRC) patients refractory to standard therapy… read more here.
Keywords: trifluridine tipiracil; tipiracil; safety; group ... See more keywords
Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study
Sign Up to like & getrecommendations! Published in 2020 at "ESMO Open"
DOI: 10.1136/esmoopen-2020-000698
Abstract: Background In RECOURSE (, trifluridine/tipiracil significantly improved overall survival and progression-free survival (PFS) versus placebo in patients with pretreated metastatic colorectal cancer (mCRC). PRECONNECT was designed to further characterise safety and clinical use of trifluridine/tipiracil.… read more here.
Keywords: metastatic colorectal; trifluridine tipiracil; tipiracil; safety ... See more keywords
[18F]fluorothymidine PET Informs the Synergistic Efficacy of Capecitabine and Trifluridine/Tipiracil in Colon Cancer.
Sign Up to like & getrecommendations! Published in 2017 at "Cancer research"
DOI: 10.1158/0008-5472.can-17-1406
Abstract: In cancer therapy, enhanced thymidine uptake by the salvage pathway can bypass dTMP depletion, thereby conferring resistance to thymidylate synthase inhibition. We investigated whether sequential combination therapy of capecitabine and trifluridine/tipiracil (TAS-102) could synergistically enhance… read more here.
Keywords: trifluridine tipiracil; tipiracil; capecitabine; cancer ... See more keywords
Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
Sign Up to like & getrecommendations! Published in 2019 at "BMC Cancer"
DOI: 10.1186/s12885-019-6475-6
Abstract: A previous phase I/II C-TASK FORCE study of trifluridine/tipiracil plus bevacizumab for patients with heavily pretreated metastatic colorectal cancer (mCRC) showed promising activity with an acceptable toxicity profile. This retrospective study aimed to investigate the… read more here.
Keywords: trifluridine tipiracil; tipiracil; tipiracil monotherapy; plus bevacizumab ... See more keywords
Metastatic Colorectal Cancer: Management with trifluridine/tipiracil
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Journal of Oncology Nursing"
DOI: 10.1188/17.cjon.e30-e37
Abstract: BACKGROUND: Treatment‐related adverse events (AEs) are common in patients with metastatic colorectal cancer (mCRC) receiving chemotherapy. These AEs may affect patient adherence, particularly with completely oral regimens, such as trifluridine/tipiracil (TAS‐102, Lonsurf®), an antimetabolite agent… read more here.
Keywords: metastatic colorectal; trifluridine tipiracil; tipiracil; colorectal cancer ... See more keywords
A budget impact model of third-line or later trifluridine/tipiracil treatment of metastatic colorectal cancer.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e15070
Abstract: e15070Background: Trifluridine/tipiracil (FTD/TPI) was recently approved for the treatment of third-line or later (3L+) metastatic colorectal cancer (mCRC). The objective of this study was to devel... read more here.
Keywords: metastatic colorectal; line later; trifluridine tipiracil; third line ... See more keywords
A phase I/II study of trifluridine/tipiracil (TAS-102) in combination with nanoliposomal irinotecan (NAL-IRI) in advanced GI cancers.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.tps4155
Abstract: TPS4155Background: Trifluridine/tipiracil (FTD/TPI, also known as TAS-102) is a combination of a nucleoside analogue and a thymidine phosphorylase inhibitor. TAS-102 has shown activity in 5FU-resis... read more here.
Keywords: 102 combination; tas 102; trifluridine tipiracil;